^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) + anastrozole (Aromatase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Overall survival outcomes of combination anastrozole and fulvestrant in molecular subsets of hormone receptor-positive breast cancer
Published date:
11/17/2020
Excerpt:
We reviewed charts of 118 pts with advanced HR+ BC who received A+F...We compared TTF and OS outcomes in pts with and without molecular aberrations including HER2 overexpression/amplification, or mutations in PIK3CA, ESR1 or BRCA1/2....Median TTF was 36 months for control vs. 10 months for BRCA mutant (HR: 0.40; 95% CI: 0.12 - 1.40, p = 0.09). Median OS was 35 months for control but has not been reached in the BRCA mutant group (HR: 1.16; 95% Cl: 0.23 - 5.88, p = 0.93).
